Lv52
1330 积分 2022-07-12 加入
WED-388 Safety, tolerability, and hepatitis B surface antigen reduction of HT-101 in chronic hepatitis B patients: preliminary results from a phase I b study
2天前
已完结
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B
2天前
已完结
Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients
3天前
已完结
The impact of HBsAg reduction via siRNA treatment on natural and vaccine (BRII-179)-induced HBV-specific humoral and cellular immune responses
3天前
已完结
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
3天前
已完结
Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA Therapeutic
7天前
已完结
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989
7天前
已完结
Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ‐73763989 in Healthy Chinese Adult Participants
7天前
已完结
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
7天前
已完结
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection
7天前
已完结
皖公网安备34019202002308
